Top

Published in:

01-09-2015 | Review

Endothelial progenitor cells support tumour growth and metastatisation: implications for the resistance to anti-angiogenic therapy

Authors: Francesco Moccia, Estella Zuccolo, Valentina Poletto, Mariapia Cinelli, Elisa Bonetti, Germano Guerra, Vittorio Rosti

Published in: Tumor Biology | Issue 9/2015

Abstract

Endothelial progenitor cells (EPCs) have recently been shown to promote the angiogenic switch in solid neoplasms, thereby promoting tumour growth and metastatisation. The genetic suppression of EPC mobilization from bone marrow prevents tumour development and colonization of remote organs. Therefore, it has been assumed that anti-angiogenic treatments, which target vascular endothelial growth factor (VEGF) signalling in both normal endothelial cells and EPCs, could interfere with EPC activation in cancer patients. Our recent data, however, show that VEGF fails to stimulate tumour endothelial colony-forming cells (ECFCs), i.e. the only EPC subtype truly belonging to the endothelial lineage. The present article will survey current evidence about EPC involvement in the angiogenic switch: we will focus on the controversy about EPC definition and on the debate around their actual incorporation into tumour neovessels. We will then discuss how ECFC insensitivity to VEGF stimulation in cancer patients could underpin their well-known resistance to anti-VEGF therapies.

Gao DC, Nolan D, McDonnell K, Vahdat L, Benezra R, Altorki N, et al. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta. 2009;1796(1):33–40. doi:10.1016/j.bbcan.2009.05.001.PubMedPubMedCentral

Moccia F, Dragoni S, Poletto V, Rosti V, Tanzi F, Ganini C, et al. Orai1 and transient receptor potential channels as novel molecular targets to impair tumor neovascularisation in renal cell carcinoma and other malignancies. Anticancer Agents Med Chem. 2014;14(2):296–312.CrossRefPubMed

Moccia F, Lodola F, Dragoni S, Bonetti E, Bottino C, Guerra G, et al. Ca2+ signalling in endothelial progenitor cells: a novel means to improve cell-based therapy and impair tumour vascularisation. Curr Vasc Pharmacol. 2014;12(1):87–105.CrossRefPubMed

Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 2007;21(12):1546–58. doi:10.1101/gad.436307.CrossRefPubMedPubMedCentral

Coghlin C, Murray GI. Current and emerging concepts in tumour metastasis. J Pathol. 2010;222(1):1–15. doi:10.1002/path.2727.CrossRefPubMed

Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307. doi:10.1038/nature10144.CrossRefPubMedPubMedCentral

Gao DC, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science. 2008;319(5860):195–8. doi:10.1126/science.1150224.CrossRefPubMed

Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820–7. doi:10.1038/nature04186.CrossRefPubMedPubMedCentral

Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011;21(2):139–46. doi:10.1016/j.semcancer.2011.01.002.CrossRefPubMed

10.

Marçola M, Rodrigues CE. Endothelial progenitor cells in tumor angiogenesis: another brick in the wall. Stem Cells Int. 2015;2015:832649. doi:10.1155/2015/832649.CrossRefPubMedPubMedCentral

11.

Moschetta M, Mishima Y, Sahin I, Manier S, Glavey S, Vacca A, et al. Role of endothelial progenitor cells in cancer progression. Biochim Biophys Acta. 2014;1846(1):26–39. doi:10.1016/j.bbcan.2014.03.005.PubMed

12.

Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006;313(5794):1785–7. doi:10.1126/science.1127592.CrossRefPubMed

13.

Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008;14(3):263–73. doi:10.1016/j.ccr.2008.08.001.CrossRefPubMedPubMedCentral

14.

Lodola F, Laforenza U, Bonetti E, Lim D, Dragoni S, Bottino C, et al. Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients. PLoS One. 2012;7(9):e42541. doi:10.1371/journal.pone.0042541.CrossRefPubMedPubMedCentral

15.

Dragoni S, Laforenza U, Bonetti E, Reforgiato M, Poletto V, Lodola F, et al. Enhanced expression of Stim, Orai, and TRPC transcripts and proteins in endothelial progenitor cells isolated from patients with primary myelofibrosis. PLoS One. 2014;9(3):e91099. doi:10.1371/journal.pone.0091099.CrossRefPubMedPubMedCentral

16.

Plummer PN, Freeman R, Taft RJ, Vider J, Sax M, Umer BA, et al. MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer Res. 2013;73(1):341–52. doi:10.1158/0008-5472.CAN-12-0271.CrossRefPubMed

17.

Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18(6):883–91. doi:10.1038/nm.2753.CrossRefPubMedPubMedCentral

18.

Bertolini F, Marighetti P, Martin-Padura I, Mancuso P, Hu-Lowe DD, Shaked Y, et al. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer. Drug Discov Today. 2011;16(23-24):1052–60. doi:10.1016/j.drudis.2011.08.007.CrossRefPubMed

19.

Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603. doi:10.1038/nrc2442.CrossRefPubMedPubMedCentral

20.

Moccia F, Poletto V. May the remodelling of the Ca(2+) toolkit in endothelial progenitor cells derived from cancer patients suggest alternative targets for anti-angiogenic treatment? Biochim Biophys Acta. 2014. doi:10.1016/j.bbamcr.2014.10.024.PubMed

21.

Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964–7.CrossRefPubMed

22.

Prater DN, Case J, Ingram DA, Yoder MC. Working hypothesis to redefine endothelial progenitor cells. Leukemia. 2007;21(6):1141–9. doi:10.1038/sj.leu.2404676.CrossRefPubMed

23.

Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol. 2007;35(7):1109–18. doi:10.1016/j.exphem.2007.04.002.CrossRefPubMed

24.

Yoder MC. Human endothelial progenitor cells. Cold Spring Harb Perspect Med. 2012;2(7):a006692.CrossRefPubMedPubMedCentral

25.

Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593–600. doi:10.1056/NEJMoa022287.CrossRefPubMed

26.

Rehman J, Li J, Orschell CM, March KL. Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003;107(8):1164–9.CrossRefPubMed

27.

Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109(5):1801–9. doi:10.1182/blood-2006-08-043471.CrossRefPubMedPubMedCentral

28.

Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008;28(9):1584–95. doi:10.1161/ATVBAHA.107.155960.CrossRefPubMedPubMedCentral

29.

Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000;97(7):3422–7. doi:10.1073/pnas.070046397.CrossRefPubMedPubMedCentral

30.

Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89(1):E1–7.CrossRefPubMed

31.

Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108(3):391–7. doi:10.1172/JCI13152.CrossRefPubMedPubMedCentral

32.

Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000;105(1):71–7. doi:10.1172/JCI8071.CrossRefPubMedPubMedCentral

33.

Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. 2004;104(9):2752–60.CrossRefPubMed

34.

Moccia F, Bonetti E, Dragoni S, Fontana J, Lodola F, Romani RB, et al. Hematopoietic progenitor and stem cells circulate by surfing on intracellular Ca2+ waves: a novel target for cell-based therapy and anti-cancer treatment? Curr Signal Transduction Ther. 2012;7(2):161–76.CrossRef

35.

de la Puente P, Muz B, Azab F, Azab AK. Cell trafficking of endothelial progenitor cells in tumor progression. Clin Cancer Res. 2013;19(13):3360–8. doi:10.1158/1078-0432.CCR-13-0462.CrossRefPubMed

36.

Tzeng HE, Chen PC, Lin KW, Lin CY, Tsai CH, Han SM, et al. Basic fibroblast growth factor induces VEGF expression in chondrosarcoma cells and subsequently promotes endothelial progenitor cell-primed angiogenesis. Clin Sci (Lond). 2015;129(2):147–58. doi:10.1042/CS20140390.CrossRef

37.

Patenaude A, Parker J, Karsan A. Involvement of endothelial progenitor cells in tumor vascularization. Microvasc Res. 2010;79(3):217–23. doi:10.1016/j.mvr.2010.01.007.CrossRefPubMed

38.

Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7(11):1194–201. doi:10.1038/nm1101-1194.CrossRefPubMed

39.

Nair R, Teo WS, Mittal V, Swarbrick A. ID proteins regulate diverse aspects of cancer progression and provide novel therapeutic opportunities. Mol Ther. 2014;22(8):1407–15. doi:10.1038/mt.2014.83.CrossRefPubMedPubMedCentral

40.

Mellick AS, Plummer PN, Nolan DJ, Gao D, Bambino K, Hahn M, et al. Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth. Cancer Res. 2010;70(18):7273–82. doi:10.1158/0008-5472.CAN-10-1142.CrossRefPubMedPubMedCentral

41.

Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005;11(3):261–2. doi:10.1038/nm1200.CrossRefPubMed

42.

Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18(14):3964–72. doi:10.1093/emboj/18.14.3964.CrossRefPubMedPubMedCentral

43.

Jung SY, Choi JH, Kwon SM, Masuda H, Asahara T, Lee YM. Decursin inhibits vasculogenesis in early tumor progression by suppression of endothelial progenitor cell differentiation and function. J Cell Biochem. 2012;113(5):1478–87. doi:10.1002/jcb.24085.PubMed

44.

Zhu H, Shao Q, Sun X, Deng Z, Yuan X, Yu D, et al. The mobilization, recruitment and contribution of bone marrow-derived endothelial progenitor cells to the tumor neovascularization occur at an early stage and throughout the entire process of hepatocellular carcinoma growth. Oncol Rep. 2012;28(4):1217–24. doi:10.3892/or.2012.1944.PubMed

45.

Ahn JB, Rha SY, Shin SJ, Jeung HC, Kim TS, Zhang X, et al. Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. Cancer Lett. 2010;288(1):124–32. doi:10.1016/j.canlet.2009.06.031.CrossRefPubMed

46.

Yu P, Ge YZ, Zhao Y, Wu JP, Wu R, Zhou LH, et al. Identification and significance of mobilized endothelial progenitor cells in tumor neovascularization of renal cell carcinoma. Tumour Biol. 2014;35(9):9331–41. doi:10.1007/s13277-014-2205-5.CrossRefPubMed

47.

Wei J, Jarmy G, Genuneit J, Debatin KM, Beltinger C. Human blood late outgrowth endothelial cells for gene therapy of cancer: determinants of efficacy. Gene Ther. 2007;14(4):344–56. doi:10.1038/sj.gt.3302860.CrossRefPubMed

48.

Bieback K, Vinci M, Elvers-Hornung S, Bartol A, Gloe T, Czabanka M, et al. Recruitment of human cord blood-derived endothelial colony-forming cells to sites of tumor angiogenesis. Cytotherapy. 2013;15(6):726–39. doi:10.1016/j.jcyt.2013.01.215.CrossRefPubMed

49.

Moccia F, Tanzi F, Munaron L. Endothelial remodelling and intracellular calcium machinery. Curr Mol Med. 2014;14(4):457–80.CrossRefPubMed

50.

Yoder MC, Ingram DA. The definition of EPCs and other bone marrow cells contributing to neoangiogenesis and tumor growth: is there common ground for understanding the roles of numerous marrow-derived cells in the neoangiogenic process? Biochim Biophys Acta. 2009;1796(1):50–4. doi:10.1016/j.bbcan.2009.04.002.PubMedPubMedCentral

51.

De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med. 2003;9(6):789–95. doi:10.1038/nm871.CrossRefPubMed

52.

Göthert JR, Gustin SE, van Eekelen JA, Schmidt U, Hall MA, Jane SM, et al. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood. 2004;104(6):1769–77. doi:10.1182/blood-2003-11-3952.CrossRefPubMed

53.

Wickersheim A, Kerber M, de Miguel LS, Plate KH, Machein MR. Endothelial progenitor cells do not contribute to tumor endothelium in primary and metastatic tumors. Int J Cancer. 2009;125(8):1771–7. doi:10.1002/ijc.24605.CrossRefPubMed

54.

Machein MR, Renninger S, de Lima-Hahn E, Plate KH. Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol. 2003;13(4):582–97.CrossRefPubMed

55.

Purhonen S, Palm J, Rossi D, Kaskenpää N, Rajantie I, Ylä-Herttuala S, et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A. 2008;105(18):6620–5. doi:10.1073/pnas.0710516105.CrossRefPubMedPubMedCentral

56.

Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, Salven P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood. 2004;104(7):2084–6. doi:10.1182/blood-2004-01-0336.CrossRefPubMedPubMedCentral

57.

Duda DG, Cohen KS, Kozin SV, Perentes JY, Fukumura D, Scadden DT, et al. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood. 2006;107(7):2774–6. doi:10.1182/blood-2005-08-3210.CrossRefPubMedPubMedCentral

58.

Spring H, Schüler T, Arnold B, Hämmerling GJ, Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci U S A. 2005;102(50):18111–6. doi:10.1073/pnas.0507158102.CrossRefPubMedPubMedCentral

59.

Ruzinova MB, Schoer RA, Gerald W, Egan JE, Pandolfi PP, Rafii S, et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell. 2003;4(4):277–89.CrossRefPubMed

60.

Basile DP, Yoder MC. Circulating and tissue resident endothelial progenitor cells. J Cell Physiol. 2014;229(1):10–6. doi:10.1002/jcp.24423.PubMed

61.

Li H, Gerald WL, Benezra R. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res. 2004;64(17):6137–43. doi:10.1158/0008-5472.CAN-04-1287.CrossRefPubMed

62.

Dragoni S, Laforenza U, Bonetti E, Lodola F, Bottino C, Berra-Romani R, et al. Vascular endothelial growth factor stimulates endothelial colony forming cells proliferation and tubulogenesis by inducing oscillations in intracellular Ca2+ concentration. Stem Cells. 2011;29(11):1898–907. doi:10.1002/stem.734.CrossRefPubMed

63.

Dragoni S, Laforenza U, Bonetti E, Lodola F, Bottino C, Guerra G, et al. Canonical transient receptor potential 3 channel triggers vascular endothelial growth factor-induced intracellular Ca2+ oscillations in endothelial progenitor cells isolated from umbilical cord blood. Stem Cells Dev. 2013;22(19):2561–80. doi:10.1089/scd.2013.0032.CrossRefPubMed

64.

Song Y, Li X, Wang D, Fu C, Zhu Z, Zou MH, et al. Transcription factor Krüppel-like factor 2 plays a vital role in endothelial colony forming cells differentiation. Cardiovasc Res. 2013;99(3):514–24. doi:10.1093/cvr/cvt113.CrossRefPubMedPubMedCentral

65.

Yu D, Chen W, Ren J, Zhang T, Yang K, Wu G, et al. VEGF-PKD1-HDAC7 signaling promotes endothelial progenitor cell migration and tube formation. Microvasc Res. 2014;91:66–72. doi:10.1016/j.mvr.2013.10.006.CrossRefPubMed

66.

Ben-Shoshan J, George J. Endothelial progenitor cells as therapeutic vectors in cardiovascular disorders: from experimental models to human trials. Pharmacol Ther. 2007;115(1):25–36. doi:10.1016/j.pharmthera.2007.03.012.CrossRefPubMed

67.

Roncalli JG, Tongers J, Renault MA, Losordo DW. Endothelial progenitor cells in regenerative medicine and cancer: a decade of research. Trends Biotechnol. 2008;26(5):276–83. doi:10.1016/j.tibtech.2008.01.005.CrossRefPubMed

68.

Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. Cardiovasc Res. 2008;78(3):413–21. doi:10.1093/cvr/cvn081.CrossRefPubMed

69.

Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med. 2012;2(7):a006502. doi:10.1101/cshperspect.a006502.CrossRefPubMedPubMedCentral

70.

Potenza DM, Guerra G, Avanzato D, Poletto V, Pareek S, Guido D, et al. Hydrogen sulphide triggers VEGF-induced intracellular Ca(2+) signals in human endothelial cells but not in their immature progenitors. Cell Calcium. 2014. doi:10.1016/j.ceca.2014.07.010.PubMed

71.

Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005;11(9):3514–22. doi:10.1158/1078-0432.CCR-04-2271.CrossRefPubMed

72.

Taylor M, Billiot F, Marty V, Rouffiac V, Cohen P, Tournay E, et al. Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov. 2012;2(5):434–49. doi:10.1158/2159-8290.CD-11-0171.CrossRefPubMed

73.

Clapham DE. Calcium signaling. Cell. 2007;131(6):1047–58. doi:10.1016/j.cell.2007.11.028.CrossRefPubMed

74.

Parekh AB. Decoding cytosolic Ca2+ oscillations. Trends Biochem Sci. 2011;36(2):78–87. doi:10.1016/j.tibs.2010.07.013.CrossRefPubMed

75.

Moccia F, Berra-Romani R, Tanzi F. Update on vascular endothelial Ca2+ signalling: a tale of ion channels, pumps and transporters. World J Biol Chem. 2012;3(7):127–58. doi:10.4331/wjbc.v3.i7.127.CrossRefPubMedPubMedCentral

76.

Moccia F, Berra-Romani R, Tanzi F. Ca2+ signalling in damaged endothelium and arterial remodelling: Do connexin hemichannels provide a suitable target to prevent in-stent restenosis? Curr Drug Ther. 2012;7(4):268–80. doi:10.2174/157488512804999109.CrossRef

77.

Munaron L, Pla AF. Endothelial calcium machinery and angiogenesis: understanding physiology to interfere with pathology. Curr Med Chem. 2009;16(35):4691–703.CrossRefPubMed

78.

Fiorio Pla A, Gkika D. Emerging role of TRP channels in cell migration: from tumor vascularization to metastasis. Front Physiol. 2013;4:311. doi:10.3389/fphys.2013.00311.CrossRefPubMedPubMedCentral

79.

Ivanova H, Vervliet T, Missiaen L, Parys JB, De Smedt H, Bultynck G. Inositol 1,4,5-trisphosphate receptor-isoform diversity in cell death and survival. Biochim Biophys Acta. 2014. doi:10.1016/j.bbamcr.2014.03.007.PubMedCentral

80.

Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4(7):517–29. doi:10.1038/nrm1155.CrossRefPubMed

81.

Moccia F, Berra-Romani R, Tritto S, Signorelli S, Taglietti V, Tanzi F. Epidermal growth factor induces intracellular Ca2+ oscillations in microvascular endothelial cells. J Cell Physiol. 2003;194:139–50. doi:10.1002/jcp.10198.CrossRefPubMed

82.

Berra-Romani R, Raqeeb A, Torres-Jácome J, Guzman-Silva A, Guerra G, Tanzi F, et al. The mechanism of injury-induced intracellular calcium concentration oscillations in the endothelium of excised rat aorta. J Vasc Res. 2012;49(1):65–76. doi:10.1159/000329618.CrossRefPubMed

83.

Zhu LP, Luo YG, Chen TX, Chen FR, Wang T, Hu Q. Ca2+ oscillation frequency regulates agonist-stimulated gene expression in vascular endothelial cells. J Cell Sci. 2008;121(15):2511–8. doi:10.1242/jcs.031997.CrossRefPubMed

84.

Moccia F, Dragoni S, Cinelli M, Montagnani S, Amato B, Rosti V, et al. How to utilize Ca2+ signals to rejuvenate the repairative phenotype of senescent endothelial progenitor cells in elderly patients affected by cardiovascular diseases: a useful therapeutic support of surgical approach? BMC Surg. 2013;13 Suppl 2:S46. doi:10.1186/1471-2482-13-S2-S46.CrossRefPubMedPubMedCentral

85.

Moccia F, Dragoni S, Lodola F, Bonetti E, Bottino C, Guerra G, et al. Store-dependent Ca(2+) entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization. Curr Med Chem. 2012;19(34):5802–18.CrossRefPubMed

86.

Li J, Cubbon RM, Wilson LA, Amer MS, McKeown L, Hou B, et al. Orai1 and CRAC channel dependence of VEGF-activated Ca2+ entry and endothelial tube formation. Circ Res. 2011;108(10):1190–8. doi:10.1161/circresaha.111.243352.CrossRefPubMedPubMedCentral

87.

Abdullaev IF, Bisaillon JM, Potier M, Gonzalez JC, Motiani RK, Trebak M. Stim1 and Orai1 mediate CRAC currents and store-operated calcium entry important for endothelial cell proliferation. Circ Res. 2008;103(11):1289–99. doi:10.1161/01.res.0000338496.95579.56.CrossRefPubMedPubMedCentral

88.

Dragoni S, Guerra G, Fiorio Pla A, Bertoni G, Rappa A, Poletto V, et al. A functional transient receptor potential vanilloid 4 (TRPV4) channel is expressed in human endothelial progenitor cells. J Cell Physiol. 2015;230(1):95–104. doi:10.1002/jcp.24686.CrossRefPubMed

89.

Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol. 2012;9(6):327–37. doi:10.1038/nrclinonc.2012.59.CrossRefPubMed

90.

Porta C, Paglino C, Imarisio I, Canipari C, Chen K, Neary M et al. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer. 2011;11. doi::10.1186/1471-2407-11-105.

91.

Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J. 2003;17(9):1159–61. doi:10.1096/fj.02-0557fje.PubMed

92.

Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer. 2010;1(1):12–25. doi:10.1177/1947601909356574.CrossRefPubMedPubMedCentral

93.

Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579–91. doi:10.1038/nrc2403.CrossRefPubMed

94.

Porta C, Paglino C, Imarisio I, Ganini C, Sacchi L, Quaglini S, et al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology. 2013;84(2):115–22. doi:10.1159/000342099.CrossRefPubMed

95.

Barcellos-Hoff MH, Lyden D, Wang TC. The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer. 2013;13(7):511–8. doi:10.1038/nrc3536.CrossRefPubMed

96.

Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011;71(15):5346–56. doi:10.1158/0008-5472.CAN-11-0241.CrossRefPubMed

97.

Suriano R, Chaudhuri D, Johnson RS, Lambers E, Ashok BT, Kishore R, et al. 17Beta-estradiol mobilizes bone marrow-derived endothelial progenitor cells to tumors. Cancer Res. 2008;68(15):6038–42. doi:10.1158/0008-5472.CAN-08-1009.CrossRefPubMed

98.

Myers C, Charboneau A, Cheung I, Hanks D, Boudreau N. Sustained expression of homeobox D10 inhibits angiogenesis. Am J Pathol. 2002;161(6):2099–109. doi:10.1016/S0002-9440(10)64488-4.CrossRefPubMedPubMedCentral

99.

Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17(3):471–94. doi:10.1007/s10456-014-9420-y.CrossRefPubMedPubMedCentral

100.

Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155–9.

Title: Endothelial progenitor cells support tumour growth and metastatisation: implications for the resistance to anti-angiogenic therapy
Authors: Francesco Moccia
Estella Zuccolo
Valentina Poletto
Mariapia Cinelli
Elisa Bonetti
Germano Guerra
Vittorio Rosti
Publication date: 01-09-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3823-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2015

Erratum to: Thioridazine specifically sensitizes drug-resistant cancer cells through highly increase in apoptosis and P-gp inhibition

Retraction Note to: Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis

Retraction Note to: Erucylphosphocholine induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells

Retraction Note to: Correlations of IFN-γ genetic polymorphisms with susceptibility to breast cancer: a meta-analysis

Tumor suppressive microRNA-200a inhibits renal cell carcinoma development by directly targeting TGFB2

miR-30 overexpression promotes glioma stem cells by regulating Jak/STAT3 signaling pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer